| In relation to Anninga et al. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. | osteosarcoma, |
| Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. | osteosarcoma, |
| E1A as a tumor suppressor gene: commentary re S. Madhusudan et al. A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. | ovarian, |
| A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. | ovarian, |
| Overexpression of the erbB-2 proto-oncogene in canine osteosarcoma cell lines and tumors. | osteosarcoma, |
| Longitudinal changes in serum HER-2/neu oncoprotein levels in trastuzumab-treated metastatic breast cancer patients. | breast, |
| Comparative assays for the HER-2/neu oncogene status in breast cancer. | breast, |
| [Expression of estrogen and progesterone receptors and oncoprotein HER-2 as a marker for clinical course and outcome in endometrioid adenocarcinoma of the uterine body (immunohistologic study)]. | uterine, |
| HER-2/neu oncogene amplification by chromogenic in situ hybridization in 130 breast cancers using tissue microarray and clinical follow-up studies. | breast, |
| Overexpression of c-erbB-2 oncoprotein and associated pathobiological factors in invasive primary breast cancer. | breast, |
| Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer. | breast, |
| Is the circulating urokinase plasminogen activator upregulated by the circulating p105 fraction of the HER-2/neu proto-oncogene in patients with cervical cancer?. | cervical, |
| Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation. | breast, |
| Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients. | oral |
| Correlation between serum HER-2 oncoprotein and patients with breast cancer. | breast, |
| Dietary fatty acids regulate the activation status of Her-2/neu (c-erbB-2) oncogene in breast cancer cells. | breast, |
| ErbB2 oncogene antibodies differentiate between the normal and diseased pancreas, and between chronic pancreatitis and pancreatic cancer. | pancreatic, |
| The HER-2/neu, a proto-oncogene, was found in about 30% of human breast cancers, promoting cancer growth and making cancer cells resistant to chemo- and radio-therapy. | breast, |
| Downregulation of wild-type p53 protein by HER-2/neu mediated PI3K pathway activation in human breast cancer cells: its effect on cell proliferation and implication for therapy. | breast, |
| Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein. | esophageal, |